Buchumschlag

The effects of co-prescription of pantoprazole on the clozapine metabolism

BACKGROUND: Polypharmacy including somatic medications such as proton pump inhibitors is a common phenomenon in psychiatric care. The aim of this study was to evaluate the pantoprazole effects on clozapine metabolism. METHODS: A large therapeutic drug-monitoring database containing plasma concentrat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kuzin, Maxim (VerfasserIn) , Schoretsanitēs, Geōrgios (VerfasserIn) , Haen, Ekkehard (VerfasserIn) , Dammann, Gerhard (VerfasserIn) , Hiemke, Christoph (VerfasserIn) , Gründer, Gerhard (VerfasserIn) , Paulzen, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2020
In: Pharmacopsychiatry
Year: 2020, Jahrgang: 53, Heft: 2, Pages: 65-70
ISSN:1439-0795
DOI:10.1055/a-1021-8827
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1021-8827
Verlag, lizenzpflichtig, Volltext: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1021-8827
Volltext
Verfasserangaben:Maxim Kuzin, Georgios Schoretsanitis, Ekkehard Haen, Gerhard Dammann, Christoph Hiemke, Gerhard Gründer, Michael Paulzen
Beschreibung
Zusammenfassung:BACKGROUND: Polypharmacy including somatic medications such as proton pump inhibitors is a common phenomenon in psychiatric care. The aim of this study was to evaluate the pantoprazole effects on clozapine metabolism. METHODS: A large therapeutic drug-monitoring database containing plasma concentrations of CLZ was analyzed. The results were stratified into four groups: a non-smoking (n=250) and a smoking group (n=326), and two groups co-medicated with pantoprazole: non-smokers (n=26) and smokers (n=29). The analysis was based on the non-parametrical Mann-Whitney U test (M-W-U) with a significance level of 0.05. RESULTS: Differences reached statistical significance for pharmacokinetic parameters between CLZ monotherapy and co-medication with pantoprazole neither in smokers nor in non-smokers (p>0.05 for M-W-U in pairwise comparisons). In patients with clozapine monotherapy, smokers had a higher daily dosage of CLZ compared to non-smokers (mean dosage 363±181 vs. 291±145 mg/day, p<0.001 for M-W-U). CONCLUSIONS: Adding pantoprazole to an ongoing treatment with clozapine does not alter the metabolism of clozapine to a significant extent.
Beschreibung:Gesehen am 25.01.2021
Beschreibung:Online Resource
ISSN:1439-0795
DOI:10.1055/a-1021-8827

Ähnliche Einträge